Your browser is no longer supported. Please, upgrade your browser.
Settings
APTO [NASD]
Aptose Biosciences Inc.
Index- P/E- EPS (ttm)-0.71 Insider Own20.40% Shs Outstand88.88M Perf Week-14.01%
Market Cap428.59M Forward P/E- EPS next Y-0.89 Insider Trans-0.11% Shs Float84.76M Perf Month-6.19%
Income-59.90M PEG- EPS next Q-0.18 Inst Own35.10% Short Float4.35% Perf Quarter8.99%
Sales- P/S- EPS this Y-28.80% Inst Trans0.81% Short Ratio0.86 Perf Half Y2.97%
Book/sh1.23 P/B3.94 EPS next Y37.20% ROA-51.90% Target Price4.72 Perf Year-37.82%
Cash/sh1.27 P/C3.82 EPS next 5Y- ROE-54.90% 52W Range3.39 - 9.00 Perf YTD10.73%
Dividend- P/FCF- EPS past 5Y7.30% ROI- 52W High-46.89% Beta1.81
Dividend %- Quick Ratio21.30 Sales past 5Y- Gross Margin- 52W Low41.00% ATR0.31
Employees39 Current Ratio21.30 Sales Q/Q- Oper. Margin- RSI (14)41.78 Volatility5.28% 5.25%
OptionableYes Debt/Eq0.00 EPS Q/Q-20.70% Profit Margin- Rel Volume0.13 Prev Close4.85
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume4.31M Price4.78
Recom2.00 SMA20-7.85% SMA50-1.43% SMA200-4.99% Volume441,988 Change-1.44%
Oct-19-20Initiated Cantor Fitzgerald Overweight $10
Sep-22-20Initiated Alliance Global Partners Buy $12
Feb-20-20Initiated Maxim Group Buy $16
Feb-06-20Reiterated H.C. Wainwright Buy $6 → $9
Jan-09-20Initiated Piper Sandler Overweight $10
Mar-01-19Initiated RBC Capital Mkts Outperform $6
Nov-16-18Initiated B. Riley FBR Buy $5
Dec-13-17Reiterated H.C. Wainwright Buy
Oct-23-17Resumed ROTH Capital Buy $5
Sep-07-17Upgrade H.C. Wainwright Neutral → Buy $1 → $4
Jun-08-17Initiated Rodman & Renshaw Neutral $1
May-04-21 04:01PM  
02:30PM  
01:29AM  
Apr-26-21 04:02PM  
Apr-08-21 07:30AM  
Mar-24-21 12:25PM  
10:25AM  
Mar-23-21 04:01PM  
03:15PM  
Mar-16-21 07:30AM  
Mar-02-21 04:02PM  
Feb-08-21 10:11AM  
Feb-02-21 11:33PM  
Jan-06-21 09:24AM  
Dec-30-20 11:25AM  
07:26AM  
Dec-18-20 08:14PM  
Dec-16-20 01:31PM  
10:53AM  
Dec-15-20 09:57AM  
Dec-14-20 01:04PM  
12:59PM  
Dec-09-20 08:48AM  
Dec-07-20 09:27AM  
09:27AM  
09:13AM  
Dec-06-20 05:30PM  
Dec-04-20 08:59AM  
08:45AM  
Dec-03-20 10:04AM  
Dec-02-20 06:03PM  
03:52PM  
08:54AM  
Dec-01-20 08:55AM  
07:30AM  
Nov-17-20 10:00AM  
Nov-10-20 04:01PM  
03:15PM  
Nov-05-20 07:02AM  
Nov-04-20 10:17AM  
Oct-27-20 04:01PM  
Oct-20-20 10:26AM  
Oct-19-20 07:00AM  
Oct-14-20 09:52PM  
Sep-15-20 07:30AM  
Sep-09-20 07:30AM  
Sep-02-20 08:50AM  
Aug-28-20 06:53AM  
Aug-26-20 10:35AM  
Aug-06-20 07:30AM  
Aug-04-20 04:01PM  
Jul-21-20 04:01PM  
04:01PM  
Jul-16-20 03:31PM  
Jul-15-20 10:49PM  
04:01PM  
Jun-29-20 07:01AM  
Jun-27-20 09:10PM  
Jun-23-20 10:50AM  
Jun-12-20 07:00AM  
Jun-02-20 05:49PM  
May-14-20 09:00AM  
May-09-20 10:28AM  
May-07-20 07:30AM  
May-06-20 09:31PM  
May-05-20 04:17PM  
04:00PM  
03:00PM  
May-03-20 07:30PM  
Apr-27-20 03:29PM  
09:00AM  
Apr-24-20 07:30AM  
Apr-21-20 07:30AM  
Apr-14-20 12:00PM  
Mar-10-20 04:02PM  
03:00PM  
Feb-25-20 07:31AM  
Feb-21-20 08:35AM  
Feb-05-20 11:52AM  
Jan-29-20 07:30AM  
07:01AM  
Jan-28-20 02:36PM  
Jan-17-20 08:44AM  
Jan-07-20 07:30AM  
Dec-19-19 04:02PM  
03:50PM  
Dec-17-19 08:00AM  
07:56AM  
Dec-16-19 04:19PM  
Dec-09-19 11:00AM  
Dec-07-19 11:00AM  
Dec-04-19 07:30AM  
Dec-02-19 07:30AM  
Nov-11-19 08:26AM  
Nov-07-19 07:30AM  
Nov-06-19 09:54AM  
Nov-05-19 04:02PM  
Oct-22-19 07:00AM  
Oct-10-19 07:30AM  
Sep-16-19 07:30AM  
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Whitehead WarrenDirectorDec 22Option Exercise2.0120,00040,20060,000Dec 28 06:00 PM
Whitehead WarrenDirectorDec 22Sale4.0620,00081,20040,000Dec 28 06:00 PM
Chow Gregory K.Executive VP & CFOJul 10Sale6.05126,668766,341232,846Jul 10 06:57 PM
Rice William G.Chair, President & CEOJul 10Sale6.05168,8911,021,791297,523Jul 10 06:55 PM
Marango JotinSenior VP, Chief Bus. OfficerJul 10Sale6.0562,835380,152116,219Jul 10 06:53 PM
Marango JotinSenior VP, Chief Bus. OfficerJul 02Sale6.3420,946132,793179,054Jul 02 08:08 PM
Whitehead WarrenDirectorJun 24Option Exercise1.9412,00023,30057,000Jun 25 06:38 PM
Whitehead WarrenDirectorJun 24Sale6.7417,000114,66040,000Jun 25 06:38 PM
Whitehead WarrenDirectorJun 23Option Exercise1.5113,00019,66263,000Jun 25 06:38 PM
Whitehead WarrenDirectorJun 23Sale7.1118,000127,89045,000Jun 25 06:38 PM